News Related to Ocrelizumab

Related coverage linked through entity extraction aliases.

New Studies Shed Light on How Epstein-Barr Virus Triggers Multiple Sclerosis

Jul 24, 2026

Two new studies clarify how Epstein-Barr virus may trigger multiple sclerosis: one shows a doubled CD4+ T cell response in untreated patients, while another reveals EBV-activated B cells cause brain inflammation in mice. Insights point to potential therapies targeting EBV-specific immune activity.

Fenebrutinib Shows 12% Reduction in Disability Progression vs Ocrelizumab in PPMS Trial

Feb 25, 2026

Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.